Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection
Purpose of Review Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as pro...
Gespeichert in:
| Veröffentlicht in: | Current heart failure reports 2021-04, Vol.18 (2), p.33-40 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 2 |
| container_start_page | 33 |
| container_title | Current heart failure reports |
| container_volume | 18 |
| creator | Zhuo, David X. Ginder, Katie Hardin, E. Ashley |
| description | Purpose of Review
Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field.
Recent Findings
The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors.
Summary
Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications. |
| doi_str_mv | 10.1007/s11897-020-00499-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475400409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475400409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-cf5751a4ca12f46efb65028121055d344a736f63f129a34f83b415ebdf7cfd553</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0E4v0DFCglTWAc28maDiEWkEBIPGrL64xRlo0TPEnB3-PdACWVx5pzrzSHsRMO5xyguiDOZ7rKoYAcQGqdiy22z5Usc62k3v6bBeyxA6IlQKGrUu-yPSEkAFewz-jRxg-MlHU-u2_bMWA2H4Mbmi5kTcju0MYhe402UL-yYbDrxWUi-1XjNh_KfBenaEdj30ckWodtqLMXFxFDE943zDMucVN8xHa8XREe_7yH7G1-83p9lz883d5fXz3kTshqyJ1XleJWOssLL0v0i1JBMeMFB6VqIaWtROlL4XmhrZB-JhaSK1zUvnK-VkocsrOpt4_d54g0mLYhh6t0CHYjmUJWKnmQoBNaTKiLHVFEb_rYtDZ-GQ5mLdtMsk2SbTayjUih05_-cdFi_Rf5tZsAMQGUVuEdo1l2Ywzp5v9qvwEkcIvi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475400409</pqid></control><display><type>article</type><title>Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection</title><source>SpringerLink Journals</source><creator>Zhuo, David X. ; Ginder, Katie ; Hardin, E. Ashley</creator><creatorcontrib>Zhuo, David X. ; Ginder, Katie ; Hardin, E. Ashley</creatorcontrib><description>Purpose of Review
Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field.
Recent Findings
The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors.
Summary
Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications.</description><identifier>ISSN: 1546-9530</identifier><identifier>EISSN: 1546-9549</identifier><identifier>DOI: 10.1007/s11897-020-00499-3</identifier><identifier>PMID: 33400150</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin ; Cardiac Surgery ; Cardiology ; Imaging ; Internal Medicine ; Medicine ; Medicine & Public Health ; Radiology ; Section Editors ; Topical Collection on Biomarkers of Heart Failure ; Vascular Surgery</subject><ispartof>Current heart failure reports, 2021-04, Vol.18 (2), p.33-40</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-cf5751a4ca12f46efb65028121055d344a736f63f129a34f83b415ebdf7cfd553</citedby><cites>FETCH-LOGICAL-c347t-cf5751a4ca12f46efb65028121055d344a736f63f129a34f83b415ebdf7cfd553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11897-020-00499-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11897-020-00499-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33400150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhuo, David X.</creatorcontrib><creatorcontrib>Ginder, Katie</creatorcontrib><creatorcontrib>Hardin, E. Ashley</creatorcontrib><title>Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection</title><title>Current heart failure reports</title><addtitle>Curr Heart Fail Rep</addtitle><addtitle>Curr Heart Fail Rep</addtitle><description>Purpose of Review
Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field.
Recent Findings
The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors.
Summary
Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications.</description><subject>Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Radiology</subject><subject>Section Editors</subject><subject>Topical Collection on Biomarkers of Heart Failure</subject><subject>Vascular Surgery</subject><issn>1546-9530</issn><issn>1546-9549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOxDAQRS0E4v0DFCglTWAc28maDiEWkEBIPGrL64xRlo0TPEnB3-PdACWVx5pzrzSHsRMO5xyguiDOZ7rKoYAcQGqdiy22z5Usc62k3v6bBeyxA6IlQKGrUu-yPSEkAFewz-jRxg-MlHU-u2_bMWA2H4Mbmi5kTcju0MYhe402UL-yYbDrxWUi-1XjNh_KfBenaEdj30ckWodtqLMXFxFDE943zDMucVN8xHa8XREe_7yH7G1-83p9lz883d5fXz3kTshqyJ1XleJWOssLL0v0i1JBMeMFB6VqIaWtROlL4XmhrZB-JhaSK1zUvnK-VkocsrOpt4_d54g0mLYhh6t0CHYjmUJWKnmQoBNaTKiLHVFEb_rYtDZ-GQ5mLdtMsk2SbTayjUih05_-cdFi_Rf5tZsAMQGUVuEdo1l2Ywzp5v9qvwEkcIvi</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Zhuo, David X.</creator><creator>Ginder, Katie</creator><creator>Hardin, E. Ashley</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210401</creationdate><title>Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection</title><author>Zhuo, David X. ; Ginder, Katie ; Hardin, E. Ashley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-cf5751a4ca12f46efb65028121055d344a736f63f129a34f83b415ebdf7cfd553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Radiology</topic><topic>Section Editors</topic><topic>Topical Collection on Biomarkers of Heart Failure</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhuo, David X.</creatorcontrib><creatorcontrib>Ginder, Katie</creatorcontrib><creatorcontrib>Hardin, E. Ashley</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current heart failure reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhuo, David X.</au><au>Ginder, Katie</au><au>Hardin, E. Ashley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection</atitle><jtitle>Current heart failure reports</jtitle><stitle>Curr Heart Fail Rep</stitle><addtitle>Curr Heart Fail Rep</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>18</volume><issue>2</issue><spage>33</spage><epage>40</epage><pages>33-40</pages><issn>1546-9530</issn><eissn>1546-9549</eissn><abstract>Purpose of Review
Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field.
Recent Findings
The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors.
Summary
Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33400150</pmid><doi>10.1007/s11897-020-00499-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1546-9530 |
| ispartof | Current heart failure reports, 2021-04, Vol.18 (2), p.33-40 |
| issn | 1546-9530 1546-9549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2475400409 |
| source | SpringerLink Journals |
| subjects | Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin Cardiac Surgery Cardiology Imaging Internal Medicine Medicine Medicine & Public Health Radiology Section Editors Topical Collection on Biomarkers of Heart Failure Vascular Surgery |
| title | Markers of Immune Function in Heart Transplantation: Implications for Immunosuppression and Screening for Rejection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A26%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Markers%20of%20Immune%20Function%20in%20Heart%20Transplantation:%20Implications%20for%20Immunosuppression%20and%20Screening%20for%20Rejection&rft.jtitle=Current%20heart%20failure%20reports&rft.au=Zhuo,%20David%20X.&rft.date=2021-04-01&rft.volume=18&rft.issue=2&rft.spage=33&rft.epage=40&rft.pages=33-40&rft.issn=1546-9530&rft.eissn=1546-9549&rft_id=info:doi/10.1007/s11897-020-00499-3&rft_dat=%3Cproquest_cross%3E2475400409%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475400409&rft_id=info:pmid/33400150&rfr_iscdi=true |